Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
申请人:Aventis Pharma Deutschland GmbH
公开号:US20040220191A1
公开(公告)日:2004-11-04
The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.
Compounds of the formula I
1
in which the radicals have the stated meanings, the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.
The introduction of amines onto aromatics without metal catalysts and chemical oxidants is synthetically challenging. Herein, we report the first example of an electrochemical cross-dehydrogenative aromatization (ECDA) reaction of saturated cyclohexanones and amines to construct anilines without additional metal catalysts and chemical oxidants. This reaction exhibits a broad scope of cyclohexanones
The present invention provides 4-amino-5-cyanopyrimidine derivatives of the formula: wherein R
1
, R
2
and R
3
are defined herein, or pharmaceutically acceptable salts thereof, having a safe and potent adenosine A2a receptor agonistic activity; and also provides an adenosine A2a receptor agonist, an intraocular pressure reducing agent, or a medicine for treating glaucoma, etc., which comprises the compound as an active ingredient.
Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments
申请人:Schwink Lothar
公开号:US20070207991A1
公开(公告)日:2007-09-06
The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.
Compounds of the formula I
in which the radicals have the stated meanings the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.
The present invention provides 4-amino-5-cyanopyrimidine derivatives of the formula: wherein R
1
, R
2
and R
3
are defined herein, or pharmaceutically acceptable salts thereof, having a safe and potent adenosine A2a receptor agonistic activity; and also provides an adenosine A2a receptor agonist, an intraocular pressure reducing agent, or a medicine for treating glaucoma, etc., which comprises the compound as an active ingredient.